Disposition of cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo

Clinical Cancer Research

Volumn 4, Issue 8, 1998, Pages 1937-1942

  Sparreboom, Alex ^a   Verweij, Jaap ^a   Van Der Burg, Maria E L ^a   Loos, Walter J ^a   Brouwer, Eric ^a   Viganò, Lucia ^b   Locatelli, Alberta ^b   De Vos, Aad I ^a   Nooter, Kees ^a   Stoter, Gerrit ^a   Gianni, Luca ^b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG DETERMINATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY FLUID COMPARTMENTS; CISPLATIN; CLINICAL TRIALS, PHASE I; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; GLYCEROL; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PHENOTYPE; SURFACE-ACTIVE AGENTS; TISSUE DISTRIBUTION;

EID: 0031872770     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Kingston, D. G. I. History and chemistry. In: W. P. McGuire and E. K. Rowinsky (eds.), Paclitaxel in Cancer Treatment, pp. 1-33. New York: Marcel Dekker Inc., 1995.
2. Verweij, J., Clavel, M., and Chevalier, B. Paclitaxel (Taxol™), and docetaxel (Taxotere). Not simply two of a kind. Ann. Oncol., 5: 495-506, 1994.
3. Hoffmann, H. Polyoxyäthylenglycerol tri-ricinoleat 35 DAC 1979. Pharm. Zeit., 30: 1730-1733, 1984.
4. Dorr, R. T. Pharmacology and toxicology of cremophor EL diluent. Ann. Pharmacother., 28: S11-S14, 1994.
5. Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., and Leyland-Jones, B. Hypersensitivity reactions from taxol. J. Clin. Oncol., 8: 1263-1268, 1990.
6. Hacker, M., Koeferl, M., and Hong, C. B. Cremophor and Emulphor induced alterations of serum lipids and lipoprotein electrophoretic patterns of dogs. Res. Commun. Chem. Pathol. Pharmacol., 31: 119-128, 1981.
7. Sykes, E., Woodburn, K., Decker, D., and Kessel, D. Effect of Cremophor EL on distribution of Taxol to serum lipoproteins. Br. J. Cancer, 70: 401-404, 1994.
8. Waugh, W. N., Trissel, L. A., and Stella, V. J. Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted infusion solutions and stored in various containers. Am. J. Hosp. Pharm., 48: 1520-1524, 1991.
9. Woodcock, D. M., Jefferson, S., Linsenmeyer, M. E., Crowther, P. J., Choijnowski, G. M., Williams, B., and Bertoncello, I. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water insoluble vitamins and drugs. Cancer Res., 50: 4199-4203, 1990.
10. Schuurhuis, G. J., Broxterman, H. M., Pinedo, H. M., Van Heijningen, T. H. M., Van Kalken, C. K., Vermorken, J. B., Spoelstra, E. C., and Lankelma, J. The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance. Br. J. Cancer, 62: 591-594, 1990.
11. Friche, E., Jensen, P. B., Sehested, M., Dement, F. J. F., and Nissen, N. N. The solvents Cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistance Ehrlich ascites tumor. Cancer Commun., 2: 297-304, 1990.
12. Sparreboom, A., Loos, W. J., Verweij, J., De Vos, A. I., Van der Burg, M. E. L., Stoter, G., and Nooter, K. Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. Anal. Biochem., 255: 171-175, 1998.
13. Gianni, L., Kearns, C. M., Giani, A., Capri, G., Vigano, L., Locatelli, A., Bonadonna, G., and Egorin, M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol., 13: 180-190, 1995.
14. Gianni, L., Vigano, L., Locatelli, A., Capri, G., Giani, A., Tarenzi, E., and Bonadonna, G. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J. Clin. Oncol., 15: 1906-1915, 1997.
15. Van der Burg, M. E. L., De Wit, R., Logmans, A., Van Lent, M., Stoter, G., and Verweij, J. Phase I study of weekly cisplatin and weekly or four weekly taxol in patients with advanced ovarian cancer. Eur. J. Cancer. 33: S245, 1997.
16. Kessel, D., Woodburn, K., Decker, D., and Sykes, E. Fractionation of Cremophor EL delineates components responsible for plasma protein alterations and multidrug resistance reversal. Oncol. Res., 7: 207-212, 1995.
17. Zor, T., and Selinger, Z. Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal. Biochem., 236: 302-308, 1996.
18. Sparreboom, A., Van Tellingen, O., Nooijen, W. J., and Beijnen, J. H. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res., 56: 2112-2115, 1996.
19. Chervinsky, D. S., Brecher, M. L., and Hoecle, M. J. Cremophor EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line. Anticancer Res., 13: 93-96, 1993.
20. Zordan-Nudo, T., Ling, V., Liu, Z., and Georges, E. Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res., 53: 5994-6000, 1993.
21. Fjällskog, M. L., Frii, L., and Bergh, J. Paclitaxel-induced cytoxicity - the effects of Cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein. Eur. J. Cancer, 30A: 687-690, 1994.
22. Slater, L., Sweet, P., Wetzel, M., Stupecky, M., and Osann, K. Comparison of cyclosporin A, verapamil, PSC-833 and Cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias. Leuk. Res., 19: 543-548, 1995.
23. Solomon, M. B., Meenan, B., Heavey, C., and Paietta, E. Differential modulation of P-glycoprotein, the multidrug resistance mediator, by Cremophor in normal versus leukemic hematopoietic cells. Blood, 86: 4385-4386, 1995.
24. Ross, D. D., Wooten, P. J., Tong, Y., Cornblatt, B., Levy, C., Sridhara, R., Lee, E. J., and Schiffer, C. A. Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and Cremophor EL. Blood, 83: 1337-1347, 1995.
25. Buckingham, L. E., Balasubramanian, M., Emanuele, R. M., Clodfelter, K. E., and Coon, J. S. Comparison of Solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents. Int. J. Cancer, 62: 436-442, 1995.
26. Watanabe, T., Nakayama, Y., Naito, M., Oh-hara, T., Itoh, Y., and Tsuruo, T. Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models. Anticancer Drugs, 7: 825-832, 1996.
27. Nooter, K., and Sonneveld, P. Clinical relevance of P-glycoprotein expression in hematological malignancies. Leuk. Res., 18: 233-243, 1994.
28. Sparreboom, A., Van Tellingen, O., Huizing, M. T., Nooijen, W. J., and Beijnen, J. H. Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. J. Chromatogr., 681: 355-361, 1996.
29. Van Tellingen, O., Sparreboom, A., Huizing, M. T., Nooijen, W. J., and Beijnen, J. H. The analysis and preliminary pharmacokinetics of Cremophor EL in human plasma. Ann. Oncol., 7: 92, 1996.
30. Rischin, D., Webster, L. K., Millward, M. J., Linahan, B. M., Toner, G. C., Woollett, A. M., Morton, C. G., and Bishop, J. F. Cremophor EL pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J. Natl. Cancer Inst., 88: 1297-1301, 1996.
31. Webster, L. K., Linsenmeyer, M., Millward, M. J., Morton, C. G., Bishop, J. F., and Woodcock, D. M. Measurement of Cremophor EL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J. Natl. Cancer Inst., 85: 1685-1690, 1993.
32. De Vos, A. I., Nooter, K., Verweij, J., Loos, W. J., Brouwer, E., De Bruijn, P., Ruijgrok, E. J., Van der Burg, M. E. L., Stoter, G., and Sparreboom, A. Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL. Ann. Oncol., 8: 1145-1150, 1997.
33. Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A., Clark, B., Sartorius, S. E., Cornblath, D. R., Hendricks, C. B., and Donehower, R. C. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J. Clin. Oncol., 9: 1692-1703, 1991.
34. Sparreboom, A., Van Tellingen, O., Nooijen, W. J., and Beijnen, J. H. Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs, 7: 78-86, 1996.
35. Webster, L. K., Cosson, E. J., Stokes, K. H., and Millward, M. J. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br. J. Cancer, 73: 522-524, 1996.
36. Rischin, D., Millward, M. J., Webster, L. K., Tinelly, K., Toner, G. C., Bishop, J. F., and Woodcock, D. M. Phase I trial of Cremophor EL and doxorubicin in patients with advanced cancer. Anticancer Drugs, 5: 43-44, 1994.
37. Holmes, F. A., Madden, T., Newman, R. A., Valero, V., Theriault, R. L., Fraschini, G., Walters, R. S., Booser, D. J., Buzdar A. U., Willey, J., and Hortobagyi, G. N. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol., 14: 2713-2721, 1996.
38. Gianni, L., Munzone, E., Capri, A., Fulfaro, F., Tarenzi, E., Villani, F., Spreafico, C., Laffranchi, A., Caraceni, A., Martini, C., Stefanelli, M., Valagussa, P., and Bonadonna, G. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J. Clin. Oncol., 13: 2688-2699, 1995.